Role of bendamustine in the treatment of chronic lymphocytic leukemia

References

• RiesLAGMelbertDKrapchoMNational cancer instituteBethesda, MDhttp://seer.cancer.gov/csr/1975_2005/, based on november 2007 SEER data submission, posted to the SEER website, 2008
   Google Scholar
• ChesonBDBennettJMGreverMNational cancer institute-sponsored working group guidelines for chronic lymphocytic leukemia: Revised guidelines for diagnosis and treatmentBlood199687499049978652811
   PubMed Web of Science ®Google Scholar
• HainsworthJDLitchySBartonJHSingle-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: A phase II trial of the minnie pearl cancer research networkJ Clin Oncol2003211746175112721250
   PubMed Web of Science ®Google Scholar
• ByrdJCMurphyTHowardRSRituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicityJ Clin Oncol2001192153216411304767
   PubMed Web of Science ®Google Scholar
• HuhnDvon SchillingCWilhelmMRituximab therapy of patients with B-cell chronic lymphocytic leukemiaBlood2001981326133111520778
   PubMed Web of Science ®Google Scholar
• O’BrienSMKantarjianHThomasDARituximab dose-escalation trial in chronic lymphocytic leukemiaJ Clin Oncol2001192165217011304768
   PubMed Web of Science ®Google Scholar
• TamCSO’BrienSWierdaWLong-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemiaBlood200811297598018411418
   PubMed Web of Science ®Google Scholar
• ByrdJCPetersonBLMorrisonVARandomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: Results from cancer and leukemia group B 9712 (CALGB 9712)Blood200310161412393429
   PubMed Web of Science ®Google Scholar
• ByrdJCRaiKPetersonBLAddition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: An updated retrospective comparative analysis of CALGB 9712 and CALGB 9011Blood2005105495315138165
   PubMed Web of Science ®Google Scholar
• HallekMFingerle-RowsonGFinkAImmunochemotherapy with fludarabine, cyclophosphamide and rituximab (FCR) versus fludarabine and cyclophosphamide (FC) improves response rates and progression-free survival of previously untreated patients with advanced chronic lymphocytic leukemiaBlood2008112125,325
   Web of Science ®Google Scholar
• FerrajoliAO’BrienSWierdaWKeatingMTreatment of patients with CLL 70 years old and older: A single center experience of 142 pateintsLeuk Lymphoma200546SupplS95S86
   Google Scholar
• OzegowskiWKrebsDIMET 3393, (-[1-methyl-5-bis-(β-chloräthyl)-aminobenzimidazolyl-(2)]-butter säurehydrochlorid, ein neues zytostatikum aus der reihi der benzimidazol-losteZbl Pharm197111010131019
   Google Scholar
• LeoniLMBaileyBReifertJBendamustine (treanda) displays a distinct pattern of cytotoxicity and unique mechanistic features compared with other alkylating agentsClin Cancer Res20081430931718172283
   PubMed Web of Science ®Google Scholar
• StrumbergDHarstrickADollKHoffmannBSeeberSBendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell linesAnticancer Drugs199674154218826610
   PubMed Web of Science ®Google Scholar
• RummelMJChowKUHoelzerDMitrouPSWeidmannEIn vitro studies with bendamustine: Enhanced activity in combination with rituximabSemin Oncol200229121412170426
   PubMed Web of Science ®Google Scholar
• ChowKUSommerladWDBoehrerSAnti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: Role of cytokines, complement, and caspasesHaematologica200287334311801463
   PubMed Web of Science ®Google Scholar
• FischerKStilgenbauerSSchweighoferCDBendamustine in combination with rituximab for patients with relapsed chronic lymphocytic leukemia: A multicentre phase II trial of the German CLL Study Group (GCLLSG)Blood2008112128,330
   Web of Science ®Google Scholar
• RummelMJAl-BatranSEKimSZBendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-hodgkin’s lymphomaJ Clin Oncol2005233383338915908650
   PubMed Web of Science ®Google Scholar
• RobinsonKSWilliamsMEvan der JagtRHPhase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-hodgkin’s lymphomaJ Clin Oncol2008264473447918626004
   PubMed Web of Science ®Google Scholar
• AivadoMSchulteKHenzeLBurgerJFinkeJHaasRBendamustine in the treatment of chronic lymphocytic leukemia: Results and future perspectivesSemin Oncol200229192212170428
   PubMed Web of Science ®Google Scholar
• BremerKHigh rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-hodgkin’s-lymphomasJ Cancer Res Clin Oncol200212860360912458340
   PubMed Web of Science ®Google Scholar
• KathRBlumenstengelKFrickeHJHoffkenKBendamustine monotherapy in advanced and refractory chronic lymphocytic leukemiaJ Cancer Res Clin Oncol2001127485411206271
   PubMed Web of Science ®Google Scholar
• BergmannMAGoebelerMEHeroldMEfficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase I/II study of the German CLL Study GroupHaematologica2005901357136416219572
   PubMed Web of Science ®Google Scholar
• LissitchkovTArnaudovGPeytchevDMerkleKPhase-I/II study to evaluate dose limiting toxicity, maximum tolerated dose, and tolerability of bendamustine HCl in pre-treated patients with B-chronic lymphocytic leukaemia (binet stages B and C) requiring therapyJ Cancer Res Clin Oncol20061329910416292542
   PubMed Web of Science ®Google Scholar
• NiederleNBalleisenLHeitWBendamustine versus fludarabine as second-line treatment for patients with chronic lymphocytic leukemia – first interim results of a randomized studyAnnals of Onclogy200819379
   Web of Science ®Google Scholar
• KnaufWULissitchkovTAldaoudABendamustine versus chlorambucil as first-line treatment in B-cell chronic lymphocytic leukemia: an updated analysis from an international phase III studyBlood2008112728,2091
   Web of Science ®Google Scholar
• KopplerHHeymannsJPandorfAWeideRBendamustine plus mitoxantrone – a new effective treatment for advanced chronic lymphocytic leukaemia: Results of a phase I/II studyLeuk Lymphoma20044591191315291348
   PubMed Web of Science ®Google Scholar
• WeideRPandorfAHeymannsJKopplerHBendamustine/Mitoxantrone/Rituximab (BMR): A very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. final results of a pilot studyLeuk Lymphoma2004452445244915621757
   PubMed Web of Science ®Google Scholar
• RaiKRPetersonBLAppelbaumFRFludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemiaN Engl J Med20003431750175711114313
   PubMed Web of Science ®Google Scholar
• CatovskyDRichardsSMatutesEAssessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 trial): A randomised controlled trialLancet200737023023917658394
   PubMed Web of Science ®Google Scholar
• FerrajoliALeeBNSchletteEJLenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemiaBlood20081115291529718334676
   PubMed Web of Science ®Google Scholar
• Chanan-KhanAMillerKCMusialLClinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: Results of a phase II studyJ Clin Oncol2006245343534917088571
   PubMed Web of Science ®Google Scholar
• HeeremaNAByrdJCAndritsosLAClinical activity of flavopiridol in relapsed and refractory chronic lymphocytic leukemia (CLL) with high-risk cytogenetic abnormalities: Updated data on 89 patientsBlood2007110914,3107
   Web of Science ®Google Scholar